Wells Fargo’s Standard BioTools LAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$109K Sell
118,752
-228,968
-66% -$277K ﹤0.01% 5062
2025
Q4
$445K Buy
347,720
+104,758
+43% +$141K ﹤0.01% 4577
2025
Q3
$316K Buy
242,962
+37,427
+18% +$49K ﹤0.01% 4647
2025
Q2
$247K Buy
205,535
+22,640
+12% +$25.1K ﹤0.01% 4647
2025
Q1
$198K Buy
182,895
+1,639
+0.9% +$2.3K ﹤0.01% 4712
2024
Q4
$317K Buy
181,256
+40,894
+29% +$76.2K ﹤0.01% 4482
2024
Q3
$271K Buy
140,362
+6,831
+5% +$13.4K ﹤0.01% 4380
2024
Q2
$236K Buy
133,531
+122,324
+1,091% +$299K ﹤0.01% 4409
2024
Q1
$30.4K Buy
11,207
+10,221
+1,037% +$24.7K ﹤0.01% 5445
2023
Q4
$2.18K Buy
986
+39
+4% +$83 ﹤0.01% 6094
2023
Q3
$2.75K Buy
947
+64
+7% +$167 ﹤0.01% 6048
2023
Q2
$1.7K Buy
883
+15
+2% +$30 ﹤0.01% 6240
2023
Q1
$1.69K Buy
868
+7
+0.8% +$14 ﹤0.01% 6256
2022
Q4
$1.01K Buy
861
+16
+2% +$20 ﹤0.01% 6184
2022
Q3
$1K Sell
845
-1,185
-58% -$1.79K ﹤0.01% 6380
2022
Q2
$3K Sell
2,030
-15,228
-88% -$37.7K ﹤0.01% 6189
2022
Q1
$62K Sell
17,258
-28,513
-62% -$98.5K ﹤0.01% 5549
2021
Q4
$179K Sell
45,771
-99,847
-69% -$467K ﹤0.01% 5327
2021
Q3
$960K Buy
145,618
+111,882
+332% +$736K ﹤0.01% 4276
2021
Q2
$208K Sell
33,736
-45,775
-58% -$245K ﹤0.01% 5014
2021
Q1
$359K Sell
79,511
-102,198
-56% -$561K ﹤0.01% 4870
2020
Q4
$1.09M Buy
181,709
+105,463
+138% +$693K ﹤0.01% 3968
2020
Q3
$566K Sell
76,246
-18,836
-20% -$130K ﹤0.01% 4251
2020
Q2
$381K Sell
95,082
-32,840
-26% -$114K ﹤0.01% 4513
2020
Q1
$325K Buy
127,922
+9,043
+8% +$29.7K ﹤0.01% 4363
2019
Q4
$413K Sell
118,879
-122,002
-51% -$429K ﹤0.01% 4520
2019
Q3
$1.12M Sell
240,881
-96,709
-29% -$762K ﹤0.01% 3756
2019
Q2
$4.16M Buy
337,590
+99,137
+42% +$1.26M ﹤0.01% 2731
2019
Q1
$3.17M Buy
238,453
+211,926
+799% +$2.23M ﹤0.01% 2971
2018
Q4
$229K Sell
26,527
-23,343
-47% -$182K ﹤0.01% 4830
2018
Q3
$374K Buy
49,870
+953
+2% +$6.78K ﹤0.01% 4637
2018
Q2
$292K Buy
48,917
+19,972
+69% +$114K ﹤0.01% 4820
2018
Q1
$169K Buy
28,945
+11,377
+65% +$74.7K ﹤0.01% 5061
2017
Q4
$103K Sell
17,568
-4,574
-21% -$25K ﹤0.01% 5291
2017
Q3
$111K Buy
22,142
+2,009
+10% +$8.45K ﹤0.01% 5192
2017
Q2
$81K Sell
20,133
-5,388
-21% -$25.5K ﹤0.01% 5255
2017
Q1
$146K Buy
25,521
+3,327
+15% +$21.1K ﹤0.01% 5002
2016
Q4
$162K Buy
22,194
+9,894
+80% +$62.1K ﹤0.01% 4878
2016
Q3
$98K Sell
12,300
-1,615
-12% -$14.8K ﹤0.01% 4923
2016
Q2
$126K Sell
13,915
-1,819
-12% -$17.1K ﹤0.01% 4678
2016
Q1
$127K Buy
15,734
+2,707
+21% +$19.5K ﹤0.01% 4677
2015
Q4
$141K Sell
13,027
-1,523
-10% -$15K ﹤0.01% 4686
2015
Q3
$118K Sell
14,550
-7,239
-33% -$114K ﹤0.01% 4774
2015
Q2
$527K Buy
21,789
+12,716
+140% +$401K ﹤0.01% 4057
2015
Q1
$382K Buy
9,073
+3,500
+63% +$138K ﹤0.01% 4103
2014
Q4
$188K Sell
5,573
-27,186
-83% -$770K ﹤0.01% 4460
2014
Q3
$803K Buy
32,759
+20,092
+159% +$565K ﹤0.01% 3618
2014
Q2
$372K Sell
12,667
-14,387
-53% -$461K ﹤0.01% 4064
2014
Q1
$1.19M Buy
27,054
+6,227
+30% +$274K ﹤0.01% 3365
2013
Q4
$798K Sell
20,827
-168,296
-89% -$4.96M ﹤0.01% 3554
2013
Q3
$4.15M Sell
189,123
-12,987
-6% -$255K ﹤0.01% 2325
2013
Q2
$3.53M Buy
+202,110
New +$3.55M ﹤0.01% 2385

Other funds holding LAB

Wells Fargo's LAB Position: Q1 2026 in Review

Wells Fargo reduced its Standard BioTools (LAB) stake by 66% in Q1 2026, selling an estimated $277K and leaving 118,752 shares worth $109K. The position accounts for ﹤0.01% of the portfolio, ranked #5062.

Wells Fargo first reported a position in LAB in Q2 2013 and has held it in 52 quarters since. The position peaked at $4.16M in Q2 2019. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

  • Wells Fargo held 118,752 shares of Standard BioTools worth $109K as of Q1 2026.
  • Wells Fargo sold 228,968 Standard BioTools shares in Q1 2026, an estimated $277K.
  • Standard BioTools made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #5062 holding.
  • Wells Fargo first reported a position in Standard BioTools in Q2 2013 and has held it in 52 quarters since.
  • Wells Fargo's Standard BioTools position peaked at $4.16M in Q2 2019.
  • 155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.